Filed by Amgen Inc. Pursuant to Rule 425
                                                under the Securities Act of 1933
                                        and deemed filed pursuant to Rule 14a-12
                                       under the Securities Exchange Act of 1934

                                            Subject Company: Immunex Corporation
                                                     Commission File No. 0-12406

This filing relates to the proposed acquisition ("Acquisition") by Amgen Inc.
("Amgen") of Immunex Corporation ("Immunex") pursuant to the terms of an
Agreement and Plan of Merger, dated as of December 16, 2001 (the "Merger
Agreement"), by and among Amgen, AMS Acquisition Inc. and Immunex. The Merger
Agreement is on file with the Securities and Exchange Commission as an exhibit
to the Current Report on Form 8-K filed by Amgen on December 17, 2001 and is
incorporated by reference into this filing.

The following Acquisition update was distributed by email to all Amgen staff on
January 30, 2002:

Memorandum  [LOGO OF AMGEN]

TO:      All Staff

FROM:    Fabrizio Bonanni, Dennis Fenton, Brian McNamee, George
         Morrow, Richard Nanula, Steve Odre, Roger M. Perlmutter, Beth
         Seidenberg, Kevin Sharer

DATE:    January 30, 2002

RE:      Immunex Acquisition Update

As we prepare for the close of the Amgen/Immunex acquisition over the next
several months, we want to keep you as informed as possible on integration
planning, regulatory progress, legal sensitivities and communications.

Integration Planning Team Established

Our Acquisition Integration team is formed and starting to plan for the
integration of the two companies, following the close of the transaction.

We are pleased to announce that Scott Foraker has been appointed to lead the
team. With Scott's knowledge of the various legal sensitivities surrounding an
acquisition, his familiarity with Amgen's Research and Development organization
and experience in managing major initiatives, he will be a tremendous asset to
the team. Scott has over seven-and-a-half years of Amgen experience and
currently holds the position of Vice President of Licensing where he has been
instrumental in Amgen's licensing and acquisition of new products and
technologies. Previously, he was

Associate General Counsel with responsibility in the Law Department for the
International, Licensing and Corporate Development functions. He also served in
other roles in the Law Department, including commencing Amgen's legal function
in Europe.

Scott will retain overall responsibility for the Licensing Department, but has
transitioned his day-to-day licensing duties to Bruce Burton so he can dedicate
himself full-time to leading the Integration effort. To effectively coordinate
integration planning activities, Scott will work closely with the Executive
Committee (and a subset of this group formed specifically to oversee the
integration), Peggy Phillips, Executive Vice President and Chief Operating
Officer of Immunex, and other members of the core integration team, who include:

o   Project Manager                          Carl LeBel
o   Chief of Staff                           Brad Crawford
o   Research & Development                   Tony Gringeri
o   Sales & Marketing                        Kevin Young
o   Regulatory                               David Goodkin
o   Operations/Quality/Process Development   Randy Hassler
o   Finance                                  Del Peterson
o   Human Resources                          John Hillins
o   Information Technology                   Ole Mikkelsen
o   Communications                           Becky Malkerson
o   Legal                                    Tom Zindrick/Ron Levy
o   Synergy                                  Jay Hagan
o   Research & Development/Immunex           Doug Williams & Dale Scott/Immunex
o   Communications/Immunex                   Valoree Dowell/Immunex

Where necessary, the core team will be supplemented with sub-teams to address
function-specific issues. The major responsibilities of the team are determining
the strategic direction for the integration and planning and coordination of all
integration activities. The major thrust of the team will be to ensure minimal
disruption to our current businesses, while meeting the business objectives of
the integration.

Regulatory Update

On the regulatory front, the acquisition is subject to review by the Federal
Trade Commission (FTC). In addition, Immunex has made the decision to divest
Leukine(R) and the company will be looking for a potential buyer.

Legal Sensitivities & Communications

Legally, the acquisition is also subject to approval by both Amgen and Immunex
shareholders. We want to remind you that there are certain legal constraints on
how much information can be shared between the companies and with staff at this
time. Within the various legal and other constraints, we will seek to provide
you with information throughout the integration process as it becomes available.


A number of staff members have asked about what information they may share with
Immunex before the closing. The FTC prohibits joint discussions and joint
actions before the closing that may change the competitive status quo.
Therefore, Amgen and Immunex staff should not share with each other information
about products or pipeline products where there is arguably competitive overlap,
or make any joint decisions about such products, if that information or decision
could impact competition. Prior to the closing, we will also be prohibited from
making any decisions on behalf of Immunex and similarly we will want to avoid
even the perception that we may be making decisions for Immunex. Because of
these legal complexities that govern our communications with Immunex, before
engaging in any joint discussion or activity with Immunex prior to closing,
please contact Scott Foraker to be certain that it is permissible.

As a reminder, it is also imperative that all acquisitions-related
communications be reviewed before it is issued, distributed or used. This
includes communications to all audiences, both internal and external, such as
employees, investors, analysts, suppliers, customers and others. In some cases,
the communications may need to be filed with the Securities and Exchange
Commission. As a first step, please contact your communications specialist to
review the acquisition-related communications before it is distributed. Key
communications contacts are as follows:

o  Operations/Quality/Process Development      Mary Oeffling at x74639
o  Research and Development                    Dave Kaye at x76692
o  Sales and Marketing                         Vinca Weatherly at x74379
o  Corporate Functions
   (Finance, Strategy, Legal, HR
   & Communications)                           Diana Campau at x77009
o  Media Relations                             Jeff Richardson at x73227
o  Investor Relations                          Cary Rosansky at x74634

These contacts will be responsible for routing all materials through Corporate
Communications who will make sure it receives the appropriate legal, regulatory
and Integration team review before it is distributed.

Additional Information and Where to Find It

In connection with Amgen's proposed acquisition of Immunex, Amgen and Immunex
intend to file with the SEC a joint proxy statement/prospectus and other
statement/prospectus and other relevant materials (when they become available),
and any other documents filed by Amgen or Immunex


with the SEC, may be obtained free of charge at the SEC's web site at In addition, investors and security holders may obtain free copies
of the documents filed with the SEC by Amgen by directing a request to: Amgen
Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, Attn: Investor
Relations. Investors and security holders may obtain free copies of the
documents filed with the SEC by Immunex by contacting Immunex's Investor
Relations department at 51 University Street, Seattle, WA 98101. Investors and
security holders are urged to read the joint proxy statement/prospectus and the
other relevant materials when they become available before making any voting or
investment decision with respect to the acquisition.

Amgen, Immunex and their respective executive officers and directors may be
deemed to be participants in the solicitation of proxies from the stockholders
of Amgen and Immunex in favor of the acquisition. Information about the
executive officers and directors of Amgen and their ownership of Amgen common
stock is set forth in the proxy statement for Amgen's 2001 Annual Meeting of
Stockholders, which was filed with the SEC on April 4, 2001. Information about
the executive officers and directors of Immunex and their ownership of Immunex
common stock is set forth in the proxy statement for Immunex's 2001 Annual
Meeting of Shareholders, which was filed with the SEC on March 16, 2001.
Investors and security holders may obtain more detailed information regarding
the direct and indirect interests of Amgen, Immunex and their respective
executive officers and directors in the acquisition by reading the joint proxy
statement/prospectus regarding the acquisition when it becomes available.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995, including statements about Amgen's anticipated acquisition of Immunex.
These statements are based on management's current expectations and beliefs and
are subject to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the forward-looking
statements. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. Risks, uncertainties
and assumptions include the possibility that the Immunex acquisition is
terminated or that there are unexpected delays in obtaining Federal Trade
Commission or other regulatory approvals; that the parties are unable to
successfully execute their integration strategies, or achieve planned synergies;
and other risks that are described in the Securities and Exchange Commission
reports filed by Amgen, including its most recent Form 10-Q.

Because forward-looking statements involve risks and uncertainties, actual
results and events may differ materially from results and events currently
expected by Amgen. Amgen assumes no obligation and expressly disclaims any duty
to update information contained in this document except as required by law.